U.S. Online Retail and Ecommerce Stock News

As of October 2025, the United States stock market is experiencing mixed signals, with the Dow Jones Industrial Average reaching record highs while gold prices plummet following a recent peak. Amid this backdrop, small-cap stocks in the S&P 600 index are drawing attention for their potential resilience and growth opportunities, especially when insider activity suggests confidence within these companies. In such an environment, identifying promising small-cap stocks involves looking for those...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

The Morning Bull - US Market Morning Update Wednesday, Oct, 22 2025 US stock futures are wavering early this morning as investors digest signals from the bond market and the latest updates on global trade talks. With the 10-year Treasury yield hovering near a multi-month low and heightened attention on the upcoming consumer price index data, anxiety is rising over the direction of interest rates and the potential economic fallout. This is putting pressure on risk sentiment as investors weigh...

Key Insights Institutions' substantial holdings in MacroGenics implies that they have significant influence over the...

Belden Inc. ( NYSE:BDC ), is not the largest company out there, but it received a lot of attention from a substantial...

Valvoline Inc. ( NYSE:VVV ), might not be a large cap stock, but it received a lot of attention from a substantial...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

W. R. Berkley (WRB) posted net profit margins of 13% for the recent period, improving from 12% a year ago. Earnings surged 20.8% over the past year, outpacing the company’s five-year annual average growth of 19%. The combination of rising profits and stronger margins grabs attention. However, with revenue projected to grow just 1.6% per year and earnings at 1.5%, both trailing the broader US market, investors may question whether the current momentum is sustainable as the company trades at a...

Equifax (EFX) delivered a notable turnaround this earnings season, with EPS climbing 17.1% year-over-year after recording a five-year average annual decline of 1.2%. Net profit margins also ticked upward to 11.1%, up from 10.1% a year earlier, underscoring an improvement in profitability. Looking ahead, the market is eyeing robust growth drivers as forecasts call for annual EPS growth of 20.24% over the next three years, which would outpace expectations for the broader US market. See our full...

Janus International Group (JBI) has caught the attention of investors after S&P Global Ratings upgraded the company’s credit rating from "B+" to "BB-" with a stable outlook. This shift highlights the company’s steady business model, low net leverage, and reliable cash flow. See our latest analysis for Janus International Group. The S&P rating upgrade comes on the heels of upbeat quarterly earnings and a $75 million share repurchase program, both of which signal management’s ongoing...

Thinking about what to do with H2O America stock? You are not alone; investors have been closely watching its price swings and wondering whether the water services company is truly undervalued or if there is more turbulence ahead. Over the past week, H2O America delivered a notable 6.3% rally, and even though it remains up 4.4% for the month, the bigger picture shows shares are recovering from a tough patch. The stock is still down 10.6% over the last year and nearly 15.2% over three years,...

GATX (GATX) reported a net profit margin of 18.1%, edging above last year’s 17.4%. Earnings are forecasted to grow at 11.2% annually, with revenue set for 5.4% yearly growth. These figures trail the broader US market’s projected pace. Recent earnings were also boosted by a one-off gain of $125.0 million. With the company’s share price currently at $163.02, investors face a mix of decelerating growth and solid profitability. This dynamic is likely to shape sentiment as they weigh short-term...

Crown Holdings (NYSE:CCK) reported a sharp jump in net profit margins to 7.8%, up from just 0.8% a year earlier. Over the past year, EPS growth soared by 865.3%, easily outpacing the company’s 15.6% average annual growth over the past five years. Revenue is expected to rise by 3.1% per year going forward, trailing the broader US market growth forecast, and shares now trade at a 12x Price-To-Earnings Ratio, below industry averages. The latest results underline profitable momentum, but slower...

BrightSpring Health Services (BTSG) has returned to profitability in the latest 12 months after previously reporting a significant one-off loss of $127 million, which had weighed on its recent results. While earnings have declined at an average rate of 18.7% per year over the past five years, analysts now anticipate a sharp turnaround, with annual earnings growth of 34.5% forecast for the next three years. This pace is well ahead of the broader US market’s 15.5% rate. This optimistic profit...

Genuine Parts (GPC) delivered annual revenue growth of 3.4%, trailing the broader US market’s 10.1% pace. The company’s earnings are forecast to climb 12.7% per year, though that also falls short of the market’s expected 15.5% growth rate. Net profit margins narrowed to 3.4% from 4.7% last year, signaling margin compression that investors will want to monitor during this earnings season. See our full analysis for Genuine Parts. Next, we will set these results against the dominant market...

This week’s picks cover: How UPS plans to cut costs and automate its way back to profitability, why Paradigm Biopharma could soar if its osteoarthritis drug wins FDA approval, and how Barrick Mining offers a hedge against U.S. fiscal chaos

Rexford Industrial Realty (REXR) reported net profit margins of 32.9%, up from 29.3% last year, highlighting robust profitability. While the company’s earnings have grown at an impressive 29.3% per year over the past five years, growth cooled to 23.8% in the most recent year. Future projections indicate a 1.6% annual earnings decline and 5.1% revenue growth, which lags behind the broader US market. Results were buoyed by an $80.1 million one-off gain, and the shares currently trade at $43.41,...

Valmont Industries (VMI) reported net profit margins of 6.3%, down from 7.3% last year, as current results reflect the impact of a one-off loss of $101.4 million over the last twelve months. The company is forecasting earnings growth of 16.2% per year, outpacing the US market’s 15.5% average, while revenue is expected to grow 3.5% annually compared to the industry’s 10.1%. With these projections, investors are likely to focus on Valmont’s path to regaining margin strength and monitoring its...

Acme United (ACU) reported a net profit margin of 5.3%, marking a decline from last year’s 10.1%. Negative earnings growth over the past year contrasts with its five-year average annual earnings increase of 9.4%. With revenue forecast to rise just 4.8% per year and earnings expected to fall 15.9% annually over the next three years, investors are scrutinizing the company’s weaker margins and muted prospects. The P/E ratio stands at 13.9x and the share price is $37.75, both below industry and...

First United (FUNC) reported standout earnings growth of 54.4% over the past year, far outpacing its 5-year average of 5.3% per year. Net profit margins reached 29.8%, rising from 22.7% in the prior year, while shares are currently trading at $36.98, well below an estimated fair value of $68.47. With only one minor risk flagged and multiple rewards highlighted, including high-quality past earnings, expanding profit and revenue, and a strong value profile, the latest results point to improved...

Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals. See our latest analysis for Perspective Therapeutics. This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...

Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication. This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy. We'll explore how Fast Track status for AlloNK and...

Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...